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Polychlorinated dibenzo-p-dioxins (PCDDs) 
and polychlorinated dibenzofurans (PCDFs), 
collectively called dioxins, are produced 
through the burning of garbage and some 
types of chemical manufacturing processes. 
Legal regulations of dioxins in the 1990s in 
Japan have achieved a 95% reduction in their 
emissions from incinerators (Ministry of the 
Environment, Government of Japan 2004). 
Some forms of polychlorinated biphenyls 
(PCBs), which are persistent organic pollut-
ants (POPs), exhibit toxic actions similar to 
2,3,7,8-tetra  chloro  dibenzo-p-dioxin (TCDD) 
and are called dioxin-like PCBs (DL-PCBs). 
PCDDs/PCDFs and DL-PCBs are widely 
persistent in the environment because they 
are lipophilic and resistant to biological and 
chemical degradation. Several congeners 
of these pollutants exhibit various biologi-
cal and toxic actions, such as dermal toxicity, 
immuno  toxicity, carcinogenicity, and adverse 
effects on reproductive, neuro  behavioral, and 
endocrine functions (Lindström et al. 1995; 
Weisglas-Kuperus 1998). Johnson et al. 
(2001) and Lee et al. (2006) have suggested 
that these actions could be induced by low-
level exposure to these pollutants. 
Metabolic syndrome, characterized by a 
cluster of metabolic disorders including central 
obesity, glucose intolerance, dyslipidemia, and 
hypertension, has been increasing in devel-
oped countries (Flegal et al. 2002; Ford 2005). 
The health impact of each component of the 
metabolic syndrome may be small, but the 
co-occurrence of several components may have 
considerably greater impact than any one alone 
(Nakanishi et al. 2003). Subjects suffering from 
metabolic syndrome may be at increased risk 
of type 2 diabetes (Lorenzo et al. 2003; Sattar 
et al. 2003) and cardiovascular diseases (Lakka 
et al. 2002; Malik et al. 2004; McNeill et al. 
2005). Recently, background environmental 
exposure to some POPs has been reported to 
be associated with increased risk of diabetes 
(Lee et al. 2006) and with increased risk of 
metabolic syndrome (Lee et al. 2007) in the 
U.S. population in the 1999–2002 National 
Health and Nutrition Examination Survey 
(NHANES). Metabolic syndrome has become 
widely preva  lent in the populations in Asian 
countries, including Japan, but whether similar 
associations exist among Asian populations 
has not been evaluated. A survey on the accu-
mulation of dioxins and related compounds 
in humans was carried out beginning in 2002 
under the supervision of the Ministry of the 
Environment, Government of Japan. In this 
article, we report the recent 5-year results of 
a cross-sectional study to evaluate the asso-
ciations of body burden levels of PCDDs, 
PCDFs, and DL-PCBs with the prevalence of 
metabolic syndrome, and with the prevalence 
of its components, among general inhabitants 
in Japan.
Materials and Methods
Survey areas and participants. We conducted 
this survey from 2002 to 2006 in Japan on 
1,374 participants (627 male and 747 female) 
15–73 years of age. The selection of survey 
areas and the recruitment of the participants 
have been reported previously (Uemura et al. 
2008). Briefly, we divided the whole of Japan 
into five regional blocks (Table 1) and selected 
a single prefecture from each regional block 
every survey year. We recruited approximately 
50 individuals in each prefecture; approxi-
mately 20 were from urban areas, 15 from 
farming village areas, and 15 from fishing vil-
lage areas, with almost equal distribution of 
age and sex among the three areas. As a whole, 
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the subjects participated from 75 different 
residential areas of 25 prefectures through 
5 survey years and were evenly distributed 
in age and sex among the urban, farming, 
and fishing village areas in each survey year. 
Participants were required to have been liv-
ing in the same area for at least 10 years, to 
have had no known occupational exposure 
to PCDDs/PCDFs and DL-PCBs, and to 
have no known severe anemia or other health 
problems that interfere with blood sampling. 
Participation in this study was essentially 
volun  tary, and after we explained the details 
of this survey, we obtained written informed 
consent from each participant. We designed 
the study to recruit at least 250 participants 
every survey year; few subjects were excluded 
because of known severe anemia or other 
health problems during the survey years. The 
study protocol was reviewed and approved by 
the Ethical Committee of the Ministry of the 
Environment, Government of Japan.
Questionnaire. We asked participants to 
complete a questionnaire to obtain data on 
individual characteristics, including body height 
and weight, residential and occupational histo-
ries, smoking and drinking habits, and past 
history of diseases and treatments. Regarding 
drinking habits, subjects were asked how often 
they had consumed beer, sake, shochu (rough 
distilled spirits), and whisky over the previ-
ous month. The frequency of each item in the 
questionnaire was classified into five categories: 
almost everyday (6 times/week), 3–4 times/
week (3.5/week), 1–2 times/week (1.5/week), 
1–2 times/month (0.35/week), and almost 
never (0.1/week). We did not specify the unit 
or portion of each item. The frequency of alco-
hol consumption was summarized as the sum 
of the frequency of each item and then divided 
into three categories: regular, ≥ 6 times/week; 
often, 1.5 to < 6 times/week; rarely or never, 
< 1.5 times/week.
Measurements. We obtained approximately 
25 mL fasting venous blood from each par-
ticipant, with 20 mL collected into Vacutainer 
tubes containing sodium heparin (VT-100H, 
Terumo, Tokyo, Japan; or 367677, Becton 
Dickinson and Company, Tokyo, Japan). 
PCDDs, PCDFs, and DL-PCBs were analyzed 
in whole blood at the Institute of General 
Science for the Environment, METOCEAN 
Environment (currently IDEA Consultants, 
Inc., Shizuoka, Japan) by isotope dilution 
high-resolution gas chromatography/mass 
spectrometry, after liquid/liquid extraction 
and gel cleanup. The detailed analytical pro-
cedure of these chemicals has been previously 
reported (Nakamura et al. 2008). Percent 
blood lipid was measured gravimetrically using 
a sulfuric ammonium-ethanol/hexane tech-
nique. Concentrations of 7 PCDD congeners, 
10 PCDF congeners, and 12 DL-PCB conge-
ners that have toxic equivalency factors (TEFs). 
The limit of detection (LOD) was 1 pg/g lipid 
for PCDDs/PCDFs with four or five chlorine 
atoms, 2 pg/g lipid for PCDDs/PCDFs with 
six or seven chlorine atoms, 4 pg/g lipid for 
PCDDs/PCDFs with eight chlorine atoms, 
and 10 pg/g lipid for DL-PCBs.
We calculated toxic equivalents (TEQs) 
using the 1998 World Health Organization 
TEF (Van den Berg et al. 1998). We assigned 
zero concentrations to pollutant levels < LOD. 
We determined high-density lipoprotein 
(HDL) cholesterol, triglycerides, and hemo-
globin A1c (HbA1c) in the blood with an 
automatic biochemical analyzer (model 7450; 
Hitachi, Tokyo, Japan). 
Blood pressure was measured in each subject 
sitting at rest. If a measurement was extremely 
high or low or far from everyday values, we 
tried again after a short rest and used the second 
measurement as the final measurement.
Assessment of metabolic syndrome. We 
assessed the prevalence of metabolic syn-
drome using a modification of the National 
Cholesterol Education Program (NCEP) 
Adult Treatment Panel III (ATP III) defini-
tion (NCEP 2002). Some studies in Asia have 
suggested that the criteria of central obesity 
proposed by the NCEP, which is based on 
the data from Caucasians, is inappropriate 
for Asian populations, whose builds are gen-
erally smaller than those of Caucasians (Ko 
et al. 2005; Tan et al. 2004). Therefore, 
we diagnosed subjects with metabolic syn-
drome when they satisfied three or more of 
the following five criteria: a) body mass index 
(BMI) ≥ 25 kg/m2 (rather than by abdominal 
waist circumference); b) serum triglycerides 
≥ 150 mg/dL; c) serum HDL < 40 mg/dL 
in men or < 50 mg/dL in women; d) systolic 
blood pressure ≥ 130 mmHg and/or diastolic 
blood pressure ≥ 85 mmHg, or self-reported 
history of physician-diagnosed hypertension; 
e) HbA1c ≥ 5.6% (rather than fasting serum 
glucose), or self-reported history of physician-
diagnosed diabetes.
The association of diabetes mellitus with 
PCBs and other POPs is well established, and 
diabetes mellitus is a partial component of 
metabolic syndrome. Therefore, we further 
investigated the associations of these pollut-
ants with metabolic syndrome in the absence 
of diabetes mellitus by excluding subjects who 
either self-reported a history of physician-
diagnosed diabetes or had plasma HbA1c 
> 6.1%. This HbA1c level predicts fasting 
plasma glucose ≥ 126 mg/dL, the standard 
for determining diabetes, with a sensitivity of 
63.2% and a specificity of 97.4% (Rohlfing 
et al. 2000).
Statistical analysis. We evaluated the sex 
difference of BMIs by the Wilcoxon rank-
sum test. We analyzed the associations of the 
TEQs of PCDDs, PCDFs, DL-PCBs, and 
total TEQs with the prevalence of metabolic 
syndrome by excluding or including prevalent 
diabetes in logistic regressions, non  adjusted 
and adjusted for age, sex, smoking and drink-
ing habits, regional block, residential area, and 
survey year. We tested the adjusted associa-
tions of the TEQs with the five components of 
metabolic syndrome in logistic regressions. We 
also evaluated separately the adjusted associa-
tions of the concentrations of the 16 selected 
congeners for which > 75% of the subjects had 
concentrations > LOD with the prevalence of 
metabolic syndrome in logistic regressions: 
1,2,3,7,8-penta (Pe) CDD, 1,2,3,6,7,8-hexa 
(Hx) CDD, 1,2,3,4,6,7,8-hepta (Hp) CDD, 
octaCDD (OCDD), 2,3,4,7,8-PeCDF, 
1,2,3,6,7,8-HxCDF, PCB-126, PCB-169, 
PCB-105, PCB-114, PCB-118, PCB-123, 
PCB-156, PCB-157, PCB-167, and PCB-189. 
In these analyses, we defined the first quartile 
(< 25th percentile) as the reference; created 
dummy variables for sex, regional block, resi-
dential area, survey year, smoking habit, and 
drinking habit; and included all except refer-
ence categories in the model. We conducted 
tests of trend using the median value for each 
quartile of the TEQs or the concentrations of 
the congeners in logistic models. All statistical 
analyses were performed using SAS software 
(version 8.2; SAS Institute Inc., Cary, NC, 
USA). All p-values are two-tailed, and we con-
sidered those < 0.05 statistically significant.
Table 1. Baseline characteristics (%) of the 
  participants. 
  Both sexes  Male  Female
 ( n = 1,374)  (n = 627)  (n = 747)
Age (years)
  15–29  20.7  22.7  19.0
  30–39  18.7  20.6  17.1
  40–49  21.9  20.3  23.3
  50–59  24.0  23.3  24.6
  60–73  14.7  13.2  15.9
Regional block
  Hokkaido/Tohoku  19.9  19.1  20.5
  Kanto/Koshin’etsu  20.0  17.2  22.4
  Tokai/Hokuriku/Kinki  20.5  24.4  17.3
  Chugoku/Shikoku  19.3  21.2  17.7
  Kyushu/Okinawa  20.3  18.0  22.2
Residential area
  Urban  40.2  37.6  42.3
  Farming village  32.0  33.0  31.2
  Fishing village  27.8  29.4  26.5
Survey year
  2002  18.9  18.7  19.0
  2003  19.8  19.6  20.0
  2004  19.2  17.9  20.4
  2005  21.0  21.5  20.5
  2006  21.2  22.3  20.2
Smoking habit
  Current  21.8  40.2  6.3
  Past  13.1  22.0  5.6
  Never  64.6  37.5  87.4
  Unknown  0.5  0.3  0.7
Drinking habit
  Regular  20.7  36.8  7.1
  Often  22.3  27.3  18.2
  Rarely or never  53.7  32.7  71.4
  Unknown  3.3  3.2  3.3Uemura et al.
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Results
The baseline characteristics of the participants 
are shown in Table 1. Of the 1,374 subjects, 
627 (45.6%) were male and 747 (54.4%) 
were female. The medians (25th–75th per-
centiles) of BMI were 23.4 (21.6–25.7) kg/
m2 and 21.6 (20.0–23.9) kg/m2 in male and 
female subjects, respectively, with a signifi-
cant difference (p < 0.001). Table 2 shows 
the prevalence of metabolic syndrome and 
its five components in the subjects. Of the 
1,374 subjects, we defined 160 (11.6%) sub-
jects as having metabolic syndrome (105 men, 
55 women). High blood pressure had a higher 
prevalence than the other components.
Table 3 lists the concentrations and 
TEQs for each PCDD, PCDF, and DL-PCB 
congener in the blood of the subjects. The 
medians of the TEQs of PCDDs, PCDFs, 
DL-PCBs, and total TEQs were 7.4, 4.5, 7.6, 
and 20 pg TEQ/g lipid, respectively.
Table 4  lists the non  adjusted and 
adjusted associations of the TEQs with the 
prevalence of metabolic syndrome. All of the 
TEQs for PCDDs, PCDFs, and DL-PCBs 
and total TEQs had significant non  adjusted 
and adjusted associations with the preva-
lence of metabolic syndrome (tests of trend 
were all significant). The highest quartile of 
total TEQs had a high adjusted odds ratio 
(OR) and 95% confidence interval (CI) of 
5.3 (2.3–13) compared with the referent. 
Table 5 lists the non  adjusted and adjusted 
associations of the TEQs with the preva-
lence of metabolic syndrome, excluding the 
subjects with prevalent diabetes. Among the 
65 diabetic subjects, we diagnosed 38 sub-
jects with metabolic syndrome. When we 
excluded prevalent diabetes from the analyses, 
we defined 122 subjects as having metabolic 
syndrome. The adjusted associations of the 
TEQs of DL-PCBs with metabolic syndrome 
were strengthened, whereas those of PCDFs 
were slightly attenuated (p for trend = 0.07). 
The adjusted associations of the TEQs 
with the prevalence of each component of 
metabolic syndrome are shown in Table 6. 
All of the TEQs of PCDDs, PCDFs, and 
DL-PCBs and total TEQs were associated 
with high blood pressure and elevated tri-
glycerides (tests of trend were all significant). 
The TEQs of PCDDs and DL-PCBs and 
total TEQs showed trends for the associations 
with high HbA1c (p for trends all < 0.01). In 
particular, the highest quartiles of DL-PCBs 
and total TEQs had adjusted ORs of 8.0 and 
8.6, respectively, in the prevalence of high 
HbA1c. Of note, the TEQ of DL-PCBs as 
well as total TEQs showed trends for the 
associations with all five components of meta-
bolic syndrome, and the ORs in the highest 
quartile of the TEQ of DL-PCBs in four of 
the five components were higher than those 
for PCDDs or PCDFs. In contrast, the TEQs 
of PCDFs were not associated with high 
BMI (p for trend = 0.56) or low HDL (p for 
trend = 0.12).
Table 7 lists the adjusted associations of 
concentrations of selected congeners with 
the prevalence of metabolic syndrome. We 
found significant trends for associations with 
metabolic syndrome for 1,2,3,7,8-PeCDD, 
1,2,3,6,7,8-HxCDD, 1,2,3,4,6,7,8-Hp-
CDD, OCDD, 2,3,4,7,8-PeCDF, PCB-126, 
PCB-105, PCB-114, PCB-118, PCB-123, 
and PCB-167. The highest quartiles of 
PCB-126 and PCB-105 had adjusted ORs 
(95%-CI) of 9.1-(4.1–21) and 7.3-(3.4–17), 
respectively, compared with the respective 
referents.
Table 2. Prevalence of metabolic syndrome and its 
five components in the participants (%).
  Both sexes  Male  Female
 ( n = 1,374)  (n = 627)  (n = 747)
Metabolic syndrome
  Yes  11.6  16.7  7.4
  No  87.0  81.5  91.6
  Unknown  1.4  1.8  1.1
Componentsa
  BMI ≥ 25 kg/m2
  Yes  23.7  32.4  16.5
  No  75.3  66.2  82.9
  Unknown  1.0  1.4  0.7
  Blood pressure ≥ 130/85 mmHg or a history 
  of physician-diagnosed hypertension
  Yes  41.3  50.4  33.7
  No  58.6  49.6  66.1
  Unknown  0.1  0.0  0.1
  Triglycerides ≥ 150 mg/dL
  Yes  16.2  26.3  7.8
  No  83.5  73.4  92.0
  Unknown  0.3  0.3  0.3
  HDL cholesterol < 40 mg/dL in men  
  or 50 mg/dL in women
  Yes  10.3  10.4  10.3
  No  89.4  89.3  89.4
  Unknown  0.3  0.3  0.3
  HbA1c ≥ 5.6% or a history of  
  physician-diagnosed diabetes
  Yes  11.2  13.4  9.4
  No  88.8  86.6  90.6
  Unknown  0.0  0.0  0.0
aWe diagnosed metabolic syndrome as the presence of 
three or more of these five components.
Table 3. Concentrations and TEQs for PCDD, PCDF, and DL-PCB congener in the blood of the subjects.
  Concentration [pg/g lipid;    TEQ [pg TEQ/g lipid;
Congener  median (25%–75%)]  TEFa  median (25%–75%)]
PCDDs
  2,3,7,8-TCDD  1.0 (0.0–2.0)  1  1.0 (0.0–2.0)
  1,2,3,7,8-PeCDD  5.0 (3.0–7.0)  1  5.0 (3.0–7.0)
  1,2,3,4,7,8-HxCDD  0.0 (0.0–3.0)  0.1  0.0 (0.0–0.30)
  1,2,3,6,7,8-HxCDD  15 (9.0–21)  0.1  1.5 (0.90–2.1)
  1,2,3,7,8,9-HxCDD  3.0 (0.0–4.0)  0.1  0.30 (0.0–0.40)
  1,2,3,4,6,7,8-HpCDD  12 (9.0–18)  0.01  0.12 (0.09–0.18)
  OCDD  140 (89–230)  0.0001  0.01 (0.01–0.02)
    Total PCDDs      7.4 (4.6–11.2)
PCDFs
  2,3,7,8-TCDF  1.0 (0.0–2.0)  0.1  0.10 (0.0–0.20)
  1,2,3,7,8-PeCDF  0.0 (0.0–0.0)  0.05  0.0 (0.0–0.0)
  2,3,4,7,8-PeCDF  7.0 (5.0–11.0)  0.5  3.5 (2.5–5.5)
  1,2,3,4,7,8-HxCDF  3.0 (0.0–4.0)  0.1  0.30 (0.0–0.40)
  1,2,3,6,7,8-HxCDF  3.0 (2.0–5.0)  0.1  0.30 (0.20–0.50)
  1,2,3,7,8,9-HxCDF  0.0 (0.0–0.0)  0.1  0.0 (0.0–0.0)
  2,3,4,6,7,8-HxCDF  0.0 (0.0–2.0)  0.1  0.0 (0.0–0.20)
  1,2,3,4,6,7,8-HpCDF  2.0 (0.0–3.0)  0.01  0.02 (0.0–0.03)
  1,2,3,4,7,8,9-HpCDF  0.0 (0.0–0.0)  0.01  0.0 (0.0–0.0)
  OCDF  0.0 (0.0–0.0)  0.0001  0.0 (0.0–0.0)
    Total PCDFs      4.5 (2.9–6.8)
Total PCDDs/PCDFs      12 (7.7–18)
PCBs
  PCB-77  0.0 (0.0–0.0)  0.0001  0.0 (0.0–0.0)
  PCB-81  0.0 (0.0–0.0)  0.0001  0.0 (0.0–0.0)
  PCB-126  40 (22–78)  0.1  4.0 (2.2–7.8)
  PCB-169  30 (20–50)  0.01  0.30 (0.20–0.50)
  Non-ortho PCBs      4.4 (2.4–8.3)
  PCB-105  1,300 (750–2,400)  0.0001  0.13 (0.08–0.24)
  PCB-114  460 (250–830)  0.0005  0.23 (0.13–0.42)
  PCB-118  7,500 (4,200–13,000)  0.0001  0.75 (0.42–1.3)
  PCB-123  100 (60–200)  0.0001  0.01 (0.01–0.02)
  PCB-156  2,800 (1,500–4,800)  0.0005  1.4 (0.75–2.4)
  PCB-157  770 (420–1,300)  0.0005  0.39 (0.21–0.65)
  PCB-167  1,300 (730–2,300)  0.00001  0.01 (0.01–0.02)
  PCB-189  320 (180–580)  0.0001  0.03 (0.02–0.06)
  Mono-ortho PCBs      3.0 (1.6–5.1)
    Total DL-PCBs      7.6 (4.4–13)
    Total TEQs      20 (12–31)
TCDF, tetrachlorodibenzofuran. 
aData from Van den Berg et al. (1998). Dioxin-like compounds and metabolic syndrome
Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r 4 | April 2009  571
Discussion
Several studies of veterans exposed to high 
levels of dioxins have suggested that one of 
the plausible diseases associated with diox-
ins is type 2 diabetes (Henriksen et al. 1997; 
Michalek et al. 1999). This association is sup-
ported by similar epidemiologic studies in 
subjects exposed to high levels of dioxins in 
Seveso, Italy (Pesatori et al. 2003), and Korean 
Vietnam veterans exposed to Agent Orange 
(Kim et al. 2003). However, a causal asso-
ciation of dioxins or other POPs with diabetes 
is far from established. Recently, low levels of 
exposure to dioxins were reported to be asso-
ciated with increased risk of diabetes (Lee et al. 
2006), and additionally with increased risk of 
metabolic syndrome (Lee et al. 2007), in the 
U.S. population in the 1999–2002 NHANES. 
Metabolic syndrome has been increasing 
in Asian countries, including Japan, with 
the Westernization of lifestyle. We studied 
whether associations similar to those found in 
the U.S. population exist among the Japanese 
population. Lee et al. (2007) investigated the 
associations between some POPs and meta-
bolic syndrome among non  diabetic subjects. 
However, excluding diabetic subjects could 
result in a sample less representative of general 
inhabitants. Therefore, in the present study we 
examined the associations both including and 
excluding the diabetic subjects.
We found that all of the TEQs of PCDDs, 
PCDFs, and DL-PCBs and total TEQs had 
significant non  adjusted and adjusted asso-
ciations with the prevalence of metabolic syn-
drome. The highest quartile of total TEQs had 
a high adjusted OR of 5.3. Analyses of each 
component of metabolic syndrome indicated 
that all of the TEQs of PCDDs, PCDFs, and 
DL-PCBs and total TEQs were associated with 
high blood pressure and elevated triglycerides. 
The TEQs of PCDDs and DL-PCBs and 
total TEQs showed significant trends for asso-
ciations with high HbA1c. In particular, the 
highest quartiles of DL-PCB TEQs and total 
TEQs had high adjusted ORs of 8.0 and 8.6, 
respectively, in the prevalence of high HbA1c. 
Also, the DL-PCB TEQs and total TEQs were 
associated with all five components of meta-
bolic syndrome, and the ORs in the highest 
quartile of the TEQ of DL-PCBs in four of 
the five components were higher than those 
for PCDDs or PCDFs. From these findings, 
of the five components of metabolic syndrome, 
high blood pressure, elevated triglycerides, and 
glucose intolerance may be most closely asso-
ciated with these pollutants, particularly with 
DL-PCBs. In contrast, high BMI was not asso-
ciated with TEQs except for DL-PCBs. Of the 
five components, high BMI might be the least 
associated with exposure to these pollutants. 
TEQ-based analyses can be justified 
if the aryl hydrocarbon (Ah) receptor is the 
mechanism involved. PCDDs/PCDFs and 
DL-PCBs that have been assigned a TEF are 
known to exhibit various biological and toxic 
actions through binding with Ah receptors, 
so we conducted the TEQ-based analyses. 
However, Lee et al. (2007) recently reported 
that the background exposure to some POPs 
may be closely related to metabolic syndrome, 
with different POPs related to different meta-
bolic syndrome traits. To examine whether 
Ah-receptor–mediated mechanisms of the 
examined pollutants are critical in their link 
to metabolic syndrome, we further analyzed 
the associations of the concentration of each 
congener separately with the prevalence of 
metabolic syndrome. We found that 12 of 
the selected 16 congeners, widely distributed 
among PCDDs, PCDFs, and DL-PCBs, had 
trends for association with metabolic syn-
drome. In particular, the highest quartiles of 
PCB-126 and PCB-105 had adjusted ORs of 
Table 4. Nonadjusted and adjusted associations of the TEQs of PCDDs, PCDFs, DL-PCBs and total TEQs 
with the prevalence of metabolic syndrome.
  OR (95% CI)
TEQs  No. of subjects  No. of cases  Nonadjusted  Adjusteda
PCDDs
  < 4.60  343  15  Referent  Referent
  ≥ 4.60 to < 7.39  344  39  2.8 (1.5–5.4)  2.2 (1.2–4.4)
  ≥ 7.39 to < 11.20  339  38  2.7 (1.5–5.2)  2.1 (1.1–4.3)
  ≥ 11.20  348  68  5.4 (3.1–10)  3.2 (1.6–6.7)
  p for trend      < 0.01  < 0.01
PCDFs
  < 2.90  330  9  Referent  Referent
  ≥ 2.90 to < 4.50  347  40  4.6 (2.3–10)  4.0 (1.9–9.3)
  ≥ 4.50 to < 6.80  352  48  5.6 (2.9–12)  4.1 (1.9–9.7)
  ≥ 6.80  345  63  8.0 (4.1–17)  4.4 (2.0–11)
  p for trend      < 0.01  0.04
DL-PCBs
  < 4.40  339  14  Referent  Referent
  ≥ 4.40 to < 7.60  339  27  2.0 (1.1–4.1)  1.9 (0.95–4.0)
  ≥ 7.60 to < 13.00  325  39  3.2 (1.7–6.2)  2.8 (1.3–6.2)
  ≥ 13.00  371  80  6.4 (3.6–12)  4.8 (2.2–11)
  p for trend      < 0.01  < 0.01
Total TEQs
  < 12.00  303  10  Referent  Referent
  ≥ 12.00 to < 20.00  363  29  2.6 (1.3–5.6)  2.3 (1.1–5.3)
  ≥ 20.00 to < 31.00  353  47  4.5 (2.3–9.7)  3.7 (1.7–8.7)
  ≥ 31.00  355  74  7.7 (4.1–16)  5.3 (2.3–13)
  p for trend      < 0.01  < 0.01
aAdjusted for age, sex, smoking habit, drinking habit, regional block, residential area, and survey year (model df = 19).
Table 5. Nonadjusted and adjusted associations of the TEQs of PCDDs, PCDFs, DL-PCBs and total TEQs 
with the prevalence of metabolic syndrome, excluding the subjects with prevalent diabetes.
  OR (95% CI) 
TEQs  No. of subjects  No. of cases  Nonadjusted  Adjusteda
PCDDs
  < 4.49  325  12  Referent  Referent
  ≥ 4.49 to < 7.27  329  31  2.7 (1.4–5.6)  2.2 (1.1–4.8)
  ≥ 7.27 to < 11.00  311  28  2.6 (1.3–5.3)  2.1 (0.99–4.7)
  ≥ 11.00  344  51  4.6 (2.5–9.2)  3.4 (1.6–7.6)
  p for trend      < 0.01  < 0.01
PCDFs
  < 2.83  326  9  Referent  Referent
  ≥ 2.83 to < 4.40  326  31  3.7 (1.8–8.3)  3.5 (1.6–8.2)
  ≥ 4.40 to < 6.60  323  37  4.5 (2.2–10)  3.8 (1.7–9.2)
  ≥ 6.60  334  45  5.5 (2.8–12)  3.8 (1.6–9.7)
  p for trend      < 0.01  0.07
DL-PCBs
  < 4.28  327  9  Referent  Referent
  ≥ 4.28 to < 7.40  320  24  2.9 (1.4–6.7)  3.1 (1.4–7.4)
  ≥ 7.40 to < 12.87  334  35  4.2 (2.1–9.4)  5.0 (2.1–13)
  ≥ 12.87  328  54  6.9 (3.5–15)  7.3 (2.9–20)
  p for trend      < 0.01  < 0.01
Total TEQs
  < 12.00  303  10  Referent  Referent
  ≥ 12.00 to < 19.00  318  22  2.2 (1.0–4.9)  2.2 (0.98–5.0)
  ≥ 19.00 to < 30.00  345  35  3.3 (1.7–7.2)  3.2 (1.4–7.6)
  ≥ 30.00  343  55  5.6 (2.9–12)  5.1 (2.1–13)
  p for trend      < 0.01  < 0.01
aAdjusted for age, sex, smoking habit, drinking habit, regional block, residential area, and survey year (model df = 19).Uemura et al.
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9.1 and 7.3, respectively, a finding consistent 
with that of the TEQ-based analyses.
We found associations of PCDD and 
PCDF TEQs with the prevalence of metabolic 
syndrome; in contrast, Lee et al. (2007) found 
no such associations. These associations in our 
TEQ-based analyses agreed with the results 
of our congener-specific analyses. Lee et al. 
(2007) also reported that the risk of metabolic 
syndrome was highest in the third quartile 
and then plateaued in the case of DL-PCBs, 
whereas we found a significant trend for the 
association between the TEQ of DL-PCBs 
and metabolic syndrome. This association 
in our study persisted or strengthened when 
diabetic subjects were excluded from the analy-
ses. Although we could not clearly explain this 
discrepancy between the findings of Lee et al. 
(2007) and ours, the difference in prevalence of 
metabolic syndrome (24.3% and 9.3%, respec-
tively, when excluding diabetic subjects) might 
influence this discrepancy. 
The associations observed in this cross-
sectional study should be carefully interpreted 
regarding cause–effect relations. For diabetic 
subjects, slower elimination of dioxins was 
not supported in a study on Vietnam vet-
erans (Michalek et al. 2003), in which no 
difference in TCDD half-life was reported 
between diabetic and non  diabetic subjects. 
However, for subjects with metabolic syn-
drome, elimination half-life of dioxins has 
not been investigated. Some previous stud-
ies have shown that individuals with higher 
BMI, which was one component of metabolic 
syndrome in our study, have reduced dioxin 
clearance (Blanck et al. 2000; Flesch-Janys 
et al. 1996). Therefore, suffering from meta-
bolic syndrome might impair the metabolism 
or the excretion of these pollutants and might 
lead to a greater accumulation in the body. 
Further prospective studies will be needed to 
clarify this causality.
Metabolic syndrome has recently become 
prevalent, whereas the body burden levels of 
PCDDs/PCDFs and DL-PCBs have a decreas-
ing trend (Konishi et al. 2001; Porta 2006; 
Wittsiepe et al. 2000). Therefore, the dose–
response relations of the TEQs or the concen-
trations of these pollutants in the blood with 
metabolic syndrome observed in this study 
or another (Lee et al. 2007) seem to conflict. 
One possible explanation is that toxic actions 
of these pollutants may be strengthened in obe-
sity. This explanation is supported by a recent 
molecular epidemiologic study of diabeto  genic 
effects of dioxin exposure, which showed an 
inverse correlation between the ratio of GLUT4 
to nuclear factor kappa B and serum dioxin 
concentrations in obesity and family history of 
diabetes (Fujiyoshi et al. 2006). To clarify this 
hypothesis in our data, we further analyzed the 
associations between the concentrations of these 
pollutants and the prevalence of each compo-
nent of metabolic syndrome except BMI after 
stratifying by BMI (≥ 25 kg/m2 and < 25 kg/
m2). However, the associations did not show 
expected tendencies (data not shown), so the 
reliability of this hypothesis should be further 
verified. Another explanation is that PCDDs/
PCDFs or DL-PCBs contribute to the occur-
rence of metabolic syndrome, but other factors 
including the Westernization of lifestyle also 
affect the occurrence of metabolic syndrome.
The strength of the present study is that 
our subjects represent the general population 
of Japan. This study has several limitations. 
First, as stated above, the findings in this study 
should be interpreted with caution regard-
ing cause–effect relationships because of the 
cross-sectional design. Second, we diagnosed 
metabolic syndrome using a criterion of BMI 
instead of waist circumference, but BMI may 
not rigorously reflect central obesity. Similarly, 
we used HbA1c as a criterion instead of fasting 
serum glucose because we did not have data on 
fasting serum glucose.
In conclusion, this representative data 
among the general population of Japan 
showed significant associations of body burden 
levels of dioxins and related compounds with 
the prevalence of metabolic syndrome. Of 
the five components of metabolic syndrome, 
high blood pressure, elevated triglycerides, 
Table 6. Adjusted ORs (95% CIs) of the prevalence of each component of metabolic syndrome by quartiles 
of the TEQs of PCDDs, PCDFs, and DL-PCBs and total TEQs (quartile 1 is the referent).
Component  Quartile 2  Quartile 3  Quartile 4  p for trend
BMI ≥ 25 kg/m2
  PCDDs  1.5 (0.97–2.2)  1.5 (0.93–2.3)  1.5 (0.91–2.4)  0.30
  PCDFs  1.3 (0.85–2.0)  1.5 (0.97–2.4)  1.3 (0.79–2.2)  0.56
  DL-PCBs  1.7 (1.1–2.6)  1.8 (1.1–3.0)  2.6 (1.5–4.7)  < 0.01
  Total TEQs  1.3 (0.86–2.1)  1.9 (1.2–3.1)  1.9 (1.1–3.3)  0.07
Blood pressure ≥ 130/85 mmHg or a history of physician-diagnosed hypertension
  PCDDs  0.99 (0.68–1.4)  1.0 (0.70–1.6)  1.6 (1.0–2.5)  0.01
  PCDFs  1.3 (0.92–2.0)  1.6 (1.1–2.4)  1.9 (1.2–3.0)  < 0.01
  DL-PCBs  1.0 (0.71–1.6)  1.1 (0.69–1.7)  1.9 (1.1–3.1)  < 0.01
  Total TEQs  1.3 (0.86–1.9)  1.2 (0.81–1.9)  1.9 (1.1–3.1)  < 0.01
Triglycerides ≥ 150 mg/dL
  PCDDs  2.1 (1.3–3.5)  2.1 (1.2–3.7)  2.7 (1.5–4.8)  < 0.01
  PCDFs  1.5 (0.87–2.5)  2.1 (1.2–3.6)  2.2 (1.2–4.1)  0.02
  DL-PCBs  2.4 (1.4–4.3)  3.4 (1.8–6.6)  5.2 (2.6–11)  < 0.01
  Total TEQs  2.0 (1.1–3.5)  3.0 (1.6–5.6)  3.8 (1.9–7.5)  < 0.01
HDL cholesterol < 40 mg/dL in males or 50 mg/dL in females
  PCDDs  1.5 (0.83–2.8)  1.8 (0.93–3.4)  3.2 (1.7–6.4)  < 0.01
  PCDFs  1.5 (0.85–2.8)  2.0 (1.0–3.7)  1.9 (0.98–4.0)  0.12
  DL-PCBs  1.1 (0.58–1.9)  1.9 (0.98–3.8)  2.1 (0.98–4.5)  0.06
  Total TEQs  1.3 (0.72–2.5)  1.9 (0.97–3.8)  2.7 (1.3–5.9)  < 0.01
HbA1c ≥ 5.6% or a history of physician-diagnosed diabetes
  PCDDs  2.7 (1.2–6.6)  3.5 (1.6–8.7)  4.6 (2.0–12)  < 0.01
  PCDFs  2.1 (0.93–5.2)  3.9 (1.8–9.6)  3.2 (1.4–8.3)  0.06
  DL-PCBs  2.1 (0.90–5.3)  3.1 (1.3–8.0)  8.0 (3.2–22)  < 0.01
  Total TEQs  3.3 (1.3–10)  4.5 (1.7–14)  8.6 (3.1–28)  < 0.01
Adjusted for age, sex, smoking habit, drinking habit, regional block, residential area, and survey year (model df = 19). 
Table 7. Adjusted ORs (95% CIs) of the prevalence of metabolic syndrome by quartiles of the concentra-
tions of the selected congeners (Q1 = referent).
Congener  Quartile 2  Quartile 3  Quartile 4  p for trend
PCDDs
  1,2,3,7,8-PeCDD  2.8 (1.2–8.4)  2.0 (0.77–6.4)  3.7 (1.4–12)  0.04
  1,2,3,6,7,8-HxCDD  2.5 (1.3–5.6)  3.0 (1.4–6.7)  3.6 (1.7–8.2)  < 0.01
  1,2,3,4,6,7,8-HpCDD  2.1 (1.1–3.8)  3.0 (1.7–5.5)  4.5 (2.4–8.6)  < 0.01
  OCDD  1.9 (1.1–3.5)  3.0 (1.7–5.5)  3.7 (2.0–6.9)  < 0.01
PCDFs
  2,3,4,7,8-PeCDF  3.8 (1.7–9.8)  4.1 (1.8–11)  5.3 (2.2–14)  < 0.01
  1,2,3,6,7,8-HxCDF  1.2 (0.40–3.7)  2.9 (1.3–7.9)  2.8 (1.2–8.0)  0.06
PCBs
  PCB-126  2.5 (1.1–5.6)  4.9 (2.4–11)  9.1 (4.1–21)  < 0.01
  PCB-169  1.7 (0.78–4.2)  1.7 (0.79–4.2)  1.4 (0.60–3.7)  0.73
  PCB-105  1.9 (0.87–4.2)  4.6 (2.3–9.9)  7.3 (3.4–17)  < 0.01
  PCB-114  3.1 (1.5–7.1)  3.6 (1.6–8.7)  6.4 (2.7–17)  < 0.01
  PCB-118  2.5 (1.3–5.3)  3.8 (1.8–8.3)  6.5 (3.0–15)  < 0.01
  PCB-123  1.8 (0.90–3.7)  3.4 (1.7–6.9)  5.9 (2.8–13)  < 0.01
  PCB-156  1.5 (0.76–3.2)  1.7 (0.78–3.7)  2.0 (0.84–4.9)  0.23
  PCB-157  1.3 (0.65–2.5)  1.1 (0.51–2.3)  1.2 (0.54–2.8)  0.81
  PCB-167  2.3 (1.1–4.8)  2.7 (1.3–6.1)  4.1 (1.8–9.7)  < 0.01
  PCB-189  0.69 (0.34–1.4)  1.1 (0.54–2.3)  0.98 (0.42–2.3)  0.79
Adjusted for age, sex, smoking habit, drinking habit, regional block, residential area, and survey year (model df = 19). Dioxin-like compounds and metabolic syndrome
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and glucose intolerance may be closely associ-
ated with the blood levels of these pollutants, 
especially with DL-PCBs. Basic studies in 
animals and further epidemiologic studies 
using longitudinal designs should be further 
conducted to define the mechanism and the 
causality between exposure to these pollutants 
and metabolic syndrome.
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